78 related articles for article (PubMed ID: 3578333)
1. Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.
Haller I
Am J Med; 1987 Apr; 82(4A):76-9. PubMed ID: 3578333
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive evaluation of ciprofloxacin in combination with beta-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa.
Haller I
Arzneimittelforschung; 1986 Feb; 36(2):226-9. PubMed ID: 2938593
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
Moody JA; Gerding DN; Peterson LR
Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
[TBL] [Abstract][Full Text] [Related]
4. Immunocompromised animal models for the study of antibiotic combinations.
Calandra T; Glauser MP
Am J Med; 1986 May; 80(5C):45-52. PubMed ID: 3087166
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and in vitro activity of the ciprofloxacin-azlocillin combination (ratio 1:10) against gram-negative bacteria from non-neutropenic haematologic patients.
Piccolomini R; Di Girolamo A; Iacone A; Fioritoni G; Cellini L; Nicoletti M; D'Antonio D
Drugs Exp Clin Res; 1991; 17(9):455-60. PubMed ID: 1822439
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic considerations in using combinations of newer beta-lactam antibiotics.
Barriere SL
Clin Pharm; 1986 Jan; 5(1):24-33. PubMed ID: 3512153
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli.
Fasching CE; Gerding DN; Peterson LR
Am J Med; 1987 Apr; 82(4A):80-6. PubMed ID: 3472465
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
9. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC
J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394
[TBL] [Abstract][Full Text] [Related]
12. Overview of preclinical studies with ciprofloxacin.
Sanders CC; Sanders WE; Goering RV
Am J Med; 1987 Apr; 82(4A):2-11. PubMed ID: 3646829
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of ciprofloxacin to parenteral antibiotics.
Speciale A; Caccamo F; Nicoletti G
J Chemother; 1989 Jul; 1(4 Suppl):154-6. PubMed ID: 16312349
[No Abstract] [Full Text] [Related]
14. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
[TBL] [Abstract][Full Text] [Related]
15. A predictive parameter of antibacterial efficacy in vivo, based on efficacy in vitro and pharmacokinetics.
Mattie H
Scand J Infect Dis Suppl; 1990; 74():133-6. PubMed ID: 2129065
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
van der Auwera P; Vandermies A; Grenier P; Klastersky J
Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
19. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future.
Mazumdar K; Asok Kumar K; Dutta NK
Int J Antimicrob Agents; 2010 Oct; 36(4):295-302. PubMed ID: 20591629
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.
Dudley MN; Mandler HD; Gilbert D; Ericson J; Mayer KH; Zinner SH
Am J Med; 1987 Apr; 82(4A):363-8. PubMed ID: 3555061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
